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ARTICLE
Dysfunction of the key ferroptosis-surveilling
systems hypersensitizes mice to tubular necrosis
during acute kidney injury
Wulf Tonnus 1,2,21, Claudia Meyer 1,2,21, Christian Steinebach 3, Alexia Belavgeni1,2,
Anne von Mässenhausen1,2, Nadia Zamora Gonzalez1,2, Francesca Maremonti1,2, Florian Gembardt 1,
Nina Himmerkus4, Markus Latk1,2, Sophie Locke1,2, Julian Marschner5, Wenjun Li6, Spencer Short 7,
Sebastian Doll8, Irina Ingold8, Bettina Proneth 8, Christoph Daniel 9, Nazanin Kabgani10, Rafael Kramann10,11,
Stephen Motika12, Paul J. Hergenrother 12, Stefan R. Bornstein 13,14,15,16,17, Christian Hugo1,
Jan Ulrich Becker18, Kerstin Amann9, Hans-Joachim Anders5, Daniel Kreisel6,19, Derek Pratt 7,
Michael Gütschow3, Marcus Conrad 8,20 & Andreas Linkermann 1,2✉
Acute kidney injury (AKI) is morphologically characterized by a synchronized plasma
membrane rupture of cells in a specific section of a nephron, referred to as acute tubular
necrosis (ATN). Whereas the involvement of necroptosis is well characterized, genetic
evidence supporting the contribution of ferroptosis is lacking. Here, we demonstrate that the
loss of ferroptosis suppressor protein 1 (Fsp1) or the targeted manipulation of the active
center of the selenoprotein glutathione peroxidase 4 (Gpx4cys/-) sensitize kidneys to tubular
ferroptosis, resulting in a unique morphological pattern of tubular necrosis. Given the unmet
medical need to clinically inhibit AKI, we generated a combined small molecule inhibitor
(Nec-1f) that simultaneously targets receptor interacting protein kinase 1 (RIPK1) and fer-
roptosis in cell lines, in freshly isolated primary kidney tubules and in mouse models of
cardiac transplantation and of AKI and improved survival in models of ischemia-reperfusion
injury. Based on genetic and pharmacological evidence, we conclude that GPX4 dysfunction
hypersensitizes mice to ATN during AKI. Additionally, we introduce Nec-1f, a solid inhibitor of
RIPK1 and weak inhibitor of ferroptosis.
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A compelling series of publications recently indicated theinvolvement of necroptosis in acute kidney injury (AKI),acute tubular necrosis (ATN), the generation of necrotic
casts, and the reduction of renal blood flow1–5. Necroptosis is
detectable in human AKI6,7. A necroptosis-independent pathway
of regulated necrosis is triggered by iron and is referred to as
ferroptosis8–11, a regulated cell death program that involves death
propagation between cells in a non-random, synchronized
manner12–15. The ferroptosis key players glutathione peroxidase 4
(GPX4)16,17 and ferroptosis suppressor protein 1 (FSP1)18,19 were
recently demonstrated to inhibit ferroptosis in a glutathione-
dependent or independent manner, respectively. The role of these
proteins in AKI has not been assessed, and genetic evidence for
the involvement of ferroptosis in AKI is lacking. From a ther-
apeutical perspective, inhibitors of necroptosis and ferroptosis
have been reported20, but no single compound has been described
that effectively inhibits necroptosis and ferroptosis to treat AKI.
Here, we provide genetic evidence for the involvement of fer-
roptosis in AKI. We also introduce Nec-1f, a combined solid
inhibitor of RIPK1 and a weak inhibitor of ferroptosis for the
treatment of AKI and potentially other diseases.
Results
Genetic evidence for the contribution of ferroptosis to acute kid-
ney injury (AKI) is lacking. Therefore, we took advantage of a
most powerful, ferroptosis-relevant mouse model, whereby the
active site selenocysteine of glutathione peroxidase 4 (Gpx4cys/flox-
mice) was site-directedly mutated to its functional redox-
competent analog cysteine17. This amino acid exchange enables
GPX4 to rescue from ferroptosis17,21, but at the same time renders
the mutant enzyme highly susceptible to peroxide-induced, irre-
versible inactivation and consequently in a reduced resistance to
ferroptosis. Tamoxifen-induced ROSA-CreERT2-Gpx4cys/flox-mice
(in the following referred to as Gpx4cys/−-mice) do not exhibit a
spontaneous renal phenotype as assessed by period acid Schiff
(PAS)-staining (Fig. S1A). In a well-established model of severe
bilateral kidney ischemia-reperfusion injury (IRI) that causes 50%
lethality after 5 days in control mice, all Gpx4cys/−-mice died
within the first 48 h of reperfusion (Fig. 1A). In a second model of
sublethal standard kidney IRI (see methods sections for details),
Gpx4cys/−-mice exhibited significantly more positivity of the lipid
peroxidation marker 4HNE (Fig. S2A, B), significantly more
structural damage in the kidneys (Fig. 1B, C), higher levels of
serum creatinine (Fig. 1D) and higher concentrations of serum
urea (Fig. 1E) 48 h following the onset of reperfusion. Higher-
resolution PAS-stained kidney sections revealed massive tubular
necrosis (Fig. S3) in the Gpx4cys/−-mice. Such vesicle-like struc-
tures inside the intact tubular basal laminar (Fig. S3), which occur
in kidney IRI of Gpx4cys/−-mice have never been reported pre-
viously to the best of our knowledge. In a model of cisplatin-
induced AKI, Gpx4cys/−-mice did not exhibit any differences in
standard readout systems (Fig. S4), indicating that GPX4 dys-
function does not sensitize to all forms of AKI. In conclusion,
these data suggest that a replacement of the active site seleno-
cysteine to cysteine in GPX4 results in GPX4 dysfunction and
hypersensitizes mice to ferroptosis in renal tubules in kidney IRI.
The ferroptosis suppressor protein 1 (FSP1) has been recently
identified as the second mainstay in ferroptosis by inhibiting
ferroptosis in a glutathione-independent manner18. Fsp1-deficient
mice do not exhibit a spontaneous renal phenotype at the age of
12 weeks (Fig. S1B). When subjected to kidney IRI, Fsp1−/−-mice
revealed a trend to higher levels of 4HNE (Fig. S2C, D) and
significantly increased amounts of tubular necrosis were detected
(Fig. 1F, G) alongside with higher serum concentrations of
creatinine (Fig. 1H) and urea (Fig. 1I). These data suggest the
existence of a GSH-independent anti-ferroptotic system that
protects renal structure and function during IRI. In comparison
to the GSH-dependent system, however, the genetic absence of
Fsp1 resulted in less dramatic sensitization to IRI. In conclusion,
the presented data add genetic evidence to the previously
reported pharmacological evidence on the role of ferroptosis
in AKI.
We and others recently reported on the fundamental con-
tribution of necroptosis in AKI2,6,22–24. To the best of our
knowledge, the pathways of necroptosis and ferroptosis are
molecularly separated, but in combination contribute to the
pathogenesis of IRI. Inhibitors of both pathways have been
described. However, to translate several inhibitors of ferroptosis
and necroptosis to clinical trials is difficult. We, therefore, set out
to design a single small molecule that inhibits both RIPK1 and
ferroptosis. Fig. S5A demonstrates the route of synthesis of the
dual-active compound Nec-1f which was purified (Fig. S5B) and
generated in sufficient amounts. Nec-1f contains a thiohydantoin
moiety (Fig. 2A), which we previously demonstrated to inhibit
kidney IRI25, and an ester-bound chlorine, which binds the
RIPK1 kinase pocket (Fig. S5C, D), as described in detail for the
necroptosis inhibitor necrostatin-1s (Nec-1s)26.
Given that the vast majority of small molecule inhibitors of
ferroptotic cell death, particularly those containing aromatic
amine moieties27–29, are radical-trapping antioxidants (RTAs)10,
we investigated whether Nec-1f possesses this reactivity. Unlike
PMC, the truncated analog of α-tocopherol, the archetype lipo-
philic RTA, Nec-1f displayed no activity in a cumene/STY-
BODIPY co-autoxidation assay30, even when present at 5-fold
higher concentration than PMC (Fig. 2B). Nec 1f was similarly
devoid of RTA activity in co-autoxidations of egg phosphati-
dylcholine lipids in STY-BODIPY-embedded liposomes29, in
stark contrast to both PMC and ferrostatin-1 (Fer-1), the pro-
totype ferroptosis inhibitor (Fig. 2C, D), confirming that Nec-1f
does not function as an RTA. To further characterize Nec-1f, we
performed an off-target analysis using 10 µM of Nec-1f
(Fig. S6A). In that assay, inhibition of 50% was reached for the
glucocorticoid receptor (GR). We, therefore, knocked down the
GR in HT1080 cells. Upon ferroptosis-induction using erastin for
24 h, GR knockdown did not result in a significant difference with
respect to a classical FACS readout (Fig. S6B), suggesting no
relevant off-target effect of Nec-1f with respect to the investigated
enzymes.
We next tested 10 µM Nec-1f alongside Nec-1s and Fer-1 in
HT29 cells, which were induced to undergo necroptosis with the
combination of TNFα, the smac mimetic birinapant, and the
caspase inhibitor zVAD-fmk (referred to as TSZ treatment). As
demonstrated in Fig. 2E, Nec-1s and Nec-1f maintained double
negativity in FACS assays for 7-AAD and annexin V, whereas
Fer-1 did not provide protection against necroptosis. Mechan-
istically, Nec-1f prevented phosphorylation of mixed-lineage
kinase domain-like (MLKL, pS358), the downstream mediator
of necroptosis in human cells (Fig. 2F). Nec-1s and Nec-1f, due to
the nature of inhibiting RIPK1 kinase activity, also prevented
phosphorylation at S166 in RIPK1 (Fig. 2G). In this experiment,
we added Fer-1 as a control compound and found that RIPK1
S166 phorphorylation was increased in the presence of zVAD-
fmk, indicating a caspase-independent unknown way of boosting
RIPK1 phosphorylation. Interestingly, the efficacy of inhibition of
MLKL-phosphorylation was comparable between Nec-1s and
Nec-1f, while Fer-1 did not prevent MLKL-phosphorylation
(Fig. 2H). These effects were not limited to human cells, as
murine NIH3T3 treated with TNFα and zVAD-fmk phenocopied
the response of HT29 cells (Fig. 2I). These data demonstrate that
Nec-1f indeed inhibits RIPK1 kinase activity, resulting in the
prevention of downstream phosphorylation of MLKL.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24712-6
2 NATURE COMMUNICATIONS |         (2021) 12:4402 | https://doi.org/10.1038/s41467-021-24712-6 | www.nature.com/naturecommunications
Following the observation that Nec-1f, unlike Fer-1, is not an
RTA, we investigated the antiferroptotic effect of Nec-1f in
comparison to Fer-1 and Nec-1s. Four classes of ferroptosis
inducers (FINs) have been described (erastin (type 1), RSL3 (type
2), FIN56 (type 3), and FINO2 (type 4))31. In addition, recent
data suggested that the thioredoxin-reductase inhibitor ferrop-
tocide might function in a related way32. We, therefore,
established dose-response curves for the four FINs and ferrop-
tocide (Fig. S7A, B) in human HT1080 cells and identified the
inhibitory properties of Fer-1, Nec-1s, and Nec-1f in these set-
tings (Fig. S7C). Fig. 3A shows a representative experiment
(quantified in Fig. S8A) and demonstrates inhibition of cell death
induction by Fer-1 and Nec-1f, but not by Nec-1s. We noticed
that Nec-1f is less effective in preventing FINO2-induced
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ferroptosis, and that FIN56 does not effectively drive ferroptosis
in this system. We set up a similar experiment with NIH3T3 cells
and obtained comparable results (Fig. 3B and Fig. S8B).
NIH3T3 cells are the only cells in our hands that are sensitive
to the induction of necroptosis (by TZ) and ferroptosis (e.g., by
RSL3). We, therefore, induced both ferroptosis and necroptosis
simultaneously in NIH3T3 cells. While NIH3T3 cells died with
any of the given treatments, Nec-1f maintained cell viability in
this model (Fig. 3C). These data indicate that Nec-1f simulta-
neously inhibits RIPK1 and ferroptosis in NIH3T3 cells.
Having confirmed the function of Nec-1f in standard cell
culture assays often used for research on regulated necrosis, we
continued to assess kidney cells. It was previously suggested that
cell death propagation in ferroptosis involves a “wave-of-death”-
like phenotype33,34. The non-random nature of RSL3-induced
necrosis of primary renal tubular cells is demonstrated in Sup-
plementary Movie S1 and Fig. 4A. We found the murine tubular
cell line MCT to be sensitive to RSL3 and FINO2-induced fer-
roptosis (Fig. S9A), and this effect was reversed by Fer-1. While
Nec-1f failed to prevent the FINO2-induced death, it inhibited
RSL3-induced annexin V / 7-AAD positivity in MCT cells
(Fig. S9A). A recently generated human kidney tubular cell line
(CD10-135, provided by Rafael Kramann) exhibited sensitivity to
all FINs, and LDH release from CD10-135 cells was reversed by
Fer-1 or Nec-1f (Fig. 4B and Fig. S9B). Interestingly, the RTA
Fer-1, but not Nec-1f, reversed the phenotype induced by fer-
roptocide (Fig. 4B and Fig. S9B). The non-random nature of cell
death propagation, in our hands, was detected in primary renal
tubular cells and the associated LDH-release was prevented by the
addition of Fer-1 (Fig. 4C) or Nec-1f (Fig. 4D). We noted a
typical morphological appearance upon RSL3 treatment in pri-
mary kidney tubular cells that was reversed by inhibition of fer-
roptosis (Fig. S10A). In conclusion, these data suggest that renal
tubular cell lines are sensitive to ferroptosis, and that ferroptosis
of primary renal tubular cells is mediated by ferroptosis in a
“wave-of-death”-like manner.
Using a standardized protocol to freshly isolate primary renal
tubules (Fig. S11), we confirmed the unique pattern of cell death
propagation in renal tubules (Supplementary Movie S2 and
Fig. 4E). Importantly, in the case of freshly isolated kidney tubules,
this cell death occurs spontaneously (Fig. 4E and Supplementary
Movie S2). In previous data14, the addition of 5 mM glycine
diminishes the LDH release, but an osmotic effect on the readout
assay cannot be ruled out in that case. We, therefore, investigated
LDH release of kidney tubules in the absence of glycine (Fig. 4F).
Nevertheless, even in conditions where glycine was added to the
media, freshly isolated primary tubules clearly exhibited higher
amounts of LDH release after 2 h of treatment with RSL3 (Fig. 4G
and Fig. S10B), and this effect was significantly attenuated by Fer-
1 or Nec-1f (Fig. 4G). Importantly, when mice were injected with
2 mg/kg of either Fer-1 or Nec-1f 30min before the kidneys were
removed and tubules were isolated in glycine-containing media,
less spontaneous LDH release was measured (Fig. 4H). Collec-
tively, these data indicate that ferroptosis drives tubular necrosis
and LDH release from kidney tubules and that Fer-1 or Nec-1f
potently inhibits this phenomenon.
Given the results of Nec-1f as a tool to inhibit RIPK1 and
ferroptosis in cell lines, primary kidney cells, and kidney tubules,
we decided to investigate hepatic microsome stability and human
plasma stability (Fig. 5A, B and Fig. S12A) and the tissue PK of
Nec-1f in plasma, whole blood, brain, kidney, heart (Fig. S12B),
liver and lung (Fig. S12C). Assessment of PK parameters revealed
a kidney tissue half-life of 211 min for Nec-1f (Fig. S12D). We
decided to test Nec-1f in murine models of acute kidney injury
and after cardiac transplantation.
Necroptosis-deficient mice were recently demonstrated to be
protected in a mouse model of Ca-oxalate (CaOx)-induced toxic
AKI2,35. We treated mice with either vehicle or 1.65 mg/kg body
weight Nec-1f. While CaOx crystal deposition was comparable in
both groups (Fig. 5C), Nec-1f reduced tubular injury (Fig. 5D).
Along similar lines, the number of TUNEL-positive cells was
significantly decreased by Nec-1f (Fig. S13). Functionally, mice
exhibited lower concentrations of serum urea (Fig. 5E) and serum
creatinine (Fig. 5F) upon Nec-1f treatment. These data suggest
that Nec-1f protects mice from a necroptosis-driven form of AKI.
We next set out to investigate whether Nec-1f can ameliorate
inflammatory responses related to IRI after transplantation of a
solid organ. We recently reported that ferroptosis triggers neu-
trophilic graft infiltration after heart transplantation36. Treatment
of recipient mice with Nec-1f (2.0 mg/kg body weight) at the time
of transplantation inhibited the recruitment of neutrophils after
reperfusion of the graft (Fig. 5G–K and Supplementary
Movies S3, S4). While Nec-1f did not alter the rate at which
neutrophils were recruited to the graft, we observed significant
increases in their rolling velocities, highly significant decreases in
their density, and highly significant reductions in their extra-
vasation when compared to grafts that were transplanted into
control recipients. Thus, similar to our previous observations with
Fer-1, Nec-1f substantially blunts neutrophil recruitment to
transplanted hearts36.
We next pretreated mice with Nec-1f (1.65 mg/kg body weight)
in a single dose intraperitoneally 15 min prior to induction of
bilateral kidney IRI. As demonstrated in Fig. 6A, 4HNE staining
of the renal tissue was attenuated (quantified in Fig. 6B). The
typical appearance of tubular necrosis post IRI was less pro-
nounced (Fig. 6C). In keeping with this finding, levels of tubular
damage (Fig. 6D) and serum levels of creatinine and urea were
lower than in the vehicle-treated mice (Fig. 6E, F). In line with the
recent concept of necroinflammation in AKI37,38, immunohis-
tochemical staining for a macrophage marker (F4/80) detected
significantly less infiltration of macrophages in the renal medulla
(Fig. 6G–I). Finally, we performed an independent experiment
employing the model of severe renal IRI (see “Methods” for
details) to directly compare the effects of 2.0 mg/kg body weight
of Fer-1, Nec-1s, and Nec-1f, respectively. As presented in the
Kaplan−Meier plot in Fig. 6J, the percentage of surviving mice
was significantly higher after a single dose of Nec-1f prior to the
onset of reperfusion.
Discussion
The inactivation of GpX4 in mice drives chronic renal injury39,
but the involvement of this system in a clinically important
Fig. 1 Genetic evidence for the contribution of ferroptosis to acute kidney injury. A Loss of the selenocysteine residue of GPX4 sensitizes mice to acute
tubular ferroptosis. Fifthteen days after induction of the Cre-driver, severe renal ischemia-reperfusion injury (IRI) was performed in Gpx4cys/− mice, and overall
survival is presented in a Kaplan−Meier plot. B Mice were induced as in (A), and standard IRI was performed. Forty-eight hours after the onset of reperfusion, B
representative microphotographs of periodic acid-Schiff (PAS)-stained histological sections of IRI-treated mice are presented and the C tubular damage score was
quantified. Serum levels of creatinine (D) and urea (E) were detected. F IRI-treated wild-type C57Bl/6 mice and Fsp1-deficient mice underwent standard renal IRI.
Forty-eight hours following the onset of reperfusion, representative PAS-stained histological sections are presented and the tubular damage score was quantified
(G). Serum concentrations of creatinine (H) and urea (I) were measured. Bar graphs represent the mean+ /− SD. * p<0.05, *** p <0.001, ****p< 0.0001.
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model of AKI was not investigated. Here, we provide genetic
evidence for the importance of this system in AKI and solid
organ transplantation. It is entirely unclear to what extent the
ubiquinone system involving FSP1 might compensate for GpX4
dysfunction. Future studies will address this question by gen-
erating combined Gpx4cys/−-Fsp1-deficient mice. However, the
overwhelming data on the contribution of necroptosis to AKI in
combination with the growing body of evidence for ferroptosis
raise important questions: Are these two cell death systems
independent in the complex setting of diseases such as AKI and
solid organ transplantation? What is the relative contribution of
each pathway? To the best of our knowledge, no convincing
piece of evidence exists so far to demonstrate an
interregulation.
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The generation of combined inhibitors to target necrotic cell
death comes with several advantages. First, compensation
mechanisms, such as those potentially common in multiple
protein-deficient murine systems, are negligible upon short-term
application. Second, drug interactions can be limited. Finally, and
most importantly, in light of potential translation into first-in-
class clinical trials, a single small molecule will be more readily
approved. Lower costs and efforts in conducting regulatory safety
Fig. 2 Nec-1f inhibits RIPK1-dependent necroptosis. A Structures of small molecules used in this study. B Representative co-autoxidations of cumene and
STY-BODIPY initiated by Azobisisobutyronitrile (AIBN) and carried out in the presence of Nec-1f or 2,2,7,8-pentamethyl-6-chromanol (PMC). C Representative
co-autoxidations of STY-BODIPY and the polyunsaturated fatty acids of egg phosphatidylcholine liposomes initiated by MeOAMVN and carried out in the
presence of Nec-1f, PMC, and Fer-1. D Inhibition rate constants (kinh) and stoichiometries (n) derived from the initial rates and lengths of the inhibited periods,
respectively, of the data in panel (C). E HT29 cells were treated for 16 h with TNFα (20 ng/ml), birinapant (1 µM), and zVAD-fmk (20 µM) (TSZ) for the
induction of necroptosis. The influence of small molecule inhibitors on necroptosis induction is shown by 7-aminoactinomycin (7-AAD) and annexin V
positivity. (n = 8 for DMSO, TSZ and Nec-1f; n = 4 for Nec-1s and Fer-1) F HT29 cells were treated for indicated times with TSZ and simultaneous Nec-1f (10
µM) treatment. pMLKL (S358) positivity is shown by western blotting, MLKL and β-actin serve as loading controls. G, H HT29 cells were treated for indicated
times with TSZ in the presence of Nec-1s (10 µM), Fer-1 (1 µM) and Nec-1f (10 µM). pMLKL (S358) and pRIPK1 (S166) are demonstrated. I NIH3T3 cells were
treated with TZ for 16 h and stained for 7-AAD and annexin V (n = 4). The bar graph shows mean +/− SD. Statistical analysis was performed using one-way
ANOVA (post hoc Tukey’s). ** p < 0.01, *** p < 0.001.
Fig. 3 Nec-1f inhibits ferroptosis. A HT1080 cells were treated for 6 or 24 h with ferroptosis inducers (FINs) or ferroptocide in the presence of Fer-1 (1
µM), Nec-1s (30 µM) or Nec-1f (30 µM), respectively, as indicated. B NIH3T3 cells were treated as in (A). C NIH3T3 cells were treated for 16 h with either
1.13 µM RSL3 alone, TZ alone, or the combination of RSL3 plus TZ. While Fer-1 or Nec-1s fail to rescue NIH3T3 cells from necrosis, Nec-1f does. Plots show
stainings of 7-aminoactinomycin (7-AAD) and annexin V (n = 3). The bar graph shows mean+ /− SD. Statistical analysis was performed using one-way
ANOVA (post hoc Tukey’s). * p < 0.05, ** p < 0.01.
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and efficacy studies compared to what is required for combina-
tion therapies will prioritize trials employing combined inhibi-
tors. However, our data suggest that while Nec-1f is a potent
inhibitor of RIPK1, the concentrations required to effectively
inhibit ferroptosis are high (30 µM in cell culture, 2.0 mg/kg body
weight in murine injury models). In addition, with respect to its
function as a ferrostatin, we failed to identify the molecular target
of Nec-1f and thus, the mechanism of action. Further modifica-
tion of Nec-1f, including the anti-ferroptosis potency, and the
identification of the molecular mechanism of action will be
required before a dual inhibitor may be tested in clinical trials.
In summary, based on two lines of genetic and pharmacolo-
gical evidence, we conclude that ferroptosis contributes to acute
kidney injury induced by IRI. In addition, we introduce Nec-1f as
a novel tool reagent to simultaneously inhibit RIPK1 and
ferroptosis.
Methods
Cell lines and cell culture. Murine NIH3T3 (Cat# CRL-1658) and human HT1080
(Cat# CCL-121™) cell lines were purchased from the American Type Culture
Collection. Mouse cortical tubule cells (MCT) were kindly provided by Alberto
Ortiz, HT29 cells were kindly provided by Simone Fulda. Immortalized human
kidney tubular epithelial CD10-135 cells were established in the Rafael Kramann
laboratory and kindly provided for this project. Cells were cultured in a humidified
5% CO2 atmosphere. HT1080, HT29, NIH3T3, and MCT cell lines were cultured in
Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher) supplemented with
10% (v/v) FBS (Thermo Fisher), 100 U/ml penicillin, and 100 μg/ml streptomycin
(Pen/Strep, Thermo Fisher). The CD10-135 cells were cultured in DMEM:F12
Glutamax (Thermo Fisher) supplemented with 10% FBS and Pen/Strep.
Cell death assays. To induce necroptosis in a human cell line, HT29 cells were
stimulated at the indicated time points with 20 ng/ml human TNFα (Biolegend), 1
μM SMAC-mimetics (Birinapant, Chemietek), and 20 μM zVAD-fmk (Sell-
eckchem, herein referred to as zVAD). For the induction of necroptosis in NIH3T3
cells, cells were incubated with 20 ng/ml TNF-α and 20 μM zVAD for indicated
time points. Ferroptosis was induced using four ferroptosis inducers (FINs): Type 1
FIN: erastin (Sigma Aldrich), type 2 FIN: RSL3 (Selleckchem), type 3 FIN: FIN56
(Sigma Aldrich), type 4 FIN: FINO2 (provided by Keith Wörpel & Brent Stock-
well). Necrosis was also induced as described32 using the thioredoxin reductase
inhibitor ferroptocide (provided by Paul J. Hergenrother). Cells were seeded in six-
well plates or petri dishes. Unless otherwise indicated, we used 5 μM erastin, 1.13
μM RSL3, 10 μM FIN56, 10 μM FINO2, and 10 μM ferroptocide (also see Sup-
plementary Table 2). After indicated time points, cells were collected and prepared
for flow cytometry, immunoblotting, and/or LDH release assays.
Fig. 4 Ferroptosis in primary tubular cells and in freshly isolated murine renal tubules is prevented by ferroptosis inhibitors. A Still images of a time-
lapse video (Supplementary movie 1) of primary murine renal tubular cells demonstrating cell death propagation (SYTOXTM Green) following ferroptosis
induction with 1.13 µM RSL3. B The human renal tubular cell line CD10-135 was treated for indicated times with type 1-4 ferroptosis inducers (erastin, RSL3,
FIN56, FINO2) or ferroptocide in the presence of Fer-1, Nec-1s, or Nec-1f. Lactate dehydrogenase (LDH) release is presented (n = 3). C Primary kidney
tubular cells were treated with RSL3 for 14 h. Note the complete reversal of LDH release by Fer-1 (n = 2). D Primary kidney tubular cells were treated with
RSL3 for 14 h in the presence of Nec-1f (n = 3). E Still images and magnifications of Supplementary movie 2 demonstrating characteristic morphological
changes (“wave of death”-like cell death progression) in freshly isolated renal tubules that were left unstimulated. F LDH release as a function of time of
freshly isolated primary kidney tubules that were left untreated in standard medium (n = 3). G LDH release from unstimulated freshly isolated primary
kidney tubules in the presence of 5 mM glycine (DMSO, 0 h, DMSO 2 h and RSL3 2 h n = 6, Fer-1 and Nec-1 n = 3). H Freshly isolated renal tubules were
cultured for 2 h in a glycine-containing medium in the presence of RSL3 in the presence of Fer-1 or Nec-1f. Representative images are presented and the
LDH-release was quantified. Note the reduction of LDH release in the presence of Nec-1f. H Freshly isolated primary kidney tubules were kept in 5 mM
glycine-containing medium. LDH release over time is demonstrated. The addition of Nec-1f or Fer-1 resulted in less LDH release at the 24-h time point. All
experiments shown are representative of two to five independent complete repetitions performed. The bar graphs show mean +/− SD. Statistical analysis
was performed using one-way ANOVA (post hoc Tukey’s). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Thirty micromolar Nec-1f was used in all
panels in this figure.
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Fig. 5 Nec-1f protects from calcium oxalate (CaOx)-induced nephropathy and reduces neutrophil recruitment after heart transplantation. A Human
microsomal stability for Nec-1f in comparison with reference substances diclofenac and propanolol. B Human plasma stability of Nec-1f was assessed in
comparison with reference substances (propantheline, verapamil) over 120min. C Mice received a single injection of 100mg/kg sodium oxalate and were
supplemented with 3% sodium oxalate in the drinking water upon treatment with the vehicle of 1.65mg/kg Nec-1f. Pizzolato staining visualizes calcium
oxalate crystal deposition in the kidneys. Quantification of CaOx crystal deposition demonstrated equal amounts of deposition in each group. D Periodic
acid-Schiff (PAS) staining in kidneys after CaOx treatment was used to assess the tubular damage. E Serum urea and F serum creatinine levels were
analyzed 24 h after the injection of CaOx. The bar graphs (C–F) show mean +/− SD. Statistical analysis was performed using two-sided students t-test. G
Two-photon intravital imaging of neutrophil (green) behavior after transplantation of B6 hearts into control untreated (top) or Nec-1f-treated (2 mg/kg)
(bottom) B6 LysM-GFP mice at indicated time points after reperfusion. Vessels were labeled red after the injection of quantum dots (q-dots). n = 4 per
experimental group. Scale bars: 30 μm. H Intravascular rolling velocities of neutrophils, I neutrophil recruitment per minute to coronary veins, J density of
neutrophils, and K percentage of extravasated neutrophils in control cardiac grafts and after treatment of recipient mice with Nec-1f. H–K Shows the mean
+/− SEM. *p < 0.05; n.s. not significant. Statistics were performed using the Mann−Whitney U test.
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Western blotting. Cells were lysed in ice-cold 10 mM Tris-HCl, pH 7.5, 50 mM
NaCl, 1% Triton X-100, 30 mM sodium pyrophosphate, 50 mM NaF, 100 μM
Na3VO4, 2 μM ZnCl2, and 1 mM phenylmethylsulfonyl fluoride (PMSF, modified
Frackelton buffer) for 30 min on ice. Insoluble material was removed by cen-
trifugation (14 000×g, 30 min, 4 °C). Protein concentration was determined using a
commercial Bradford assay kit according to the manufacturer’s instructions
(Thermo Fisher). Equal amounts of protein (typically 30 μg per lane) were resolved
on a 4%−15% gradient SDS/PAGE gel and transferred to a PVDF membrane
(BIO-RAD). Primary antibody incubation was performed for anti-pS166-RIPK1
(Cell Signaling, Cat# 65746, 1:1000 dilution), anti-pS358-MLKL, (Abcam,
ab187091, 1:1000 dilution), anti-MLKL (Genetex, GTX107538, 1:1000 dilution)
and anti-β-Actin (Cell Signaling, Cat# 3700S, 1:1000 dilution). Secondary anti-
bodies (anti-mouse, HRP-linked antibody, Cell Signaling, Cat# 7076S; anti-rabbit,
HRP-linked antibody, Cell Signaling, Cat# 7074S) were applied at concentrations of
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1:5.000 (also see Supplementary Table 1 for details). Proteins were then visualized
by enhanced chemiluminescence (ECL; Amersham Biosciences).
Flow cytometry. Cells were harvested and the pellets were washed twice in PBS
and stained with 5 μl of 7-AAD (BD Biosciences) and 5 μl of annexin-V-FITC (BD
Biosciences) added to 100 μl annexin-V binding buffer (BD Biosciences). After 15
min, cells were recorded on the LSRII with the FACS Diva 6.1.1 software (BD
Biosciences) and subsequently analyzed with the FlowJo v10 software (Tree Star).
LDH release assay. The LDH release of cells or of freshly isolated kidney tubules
was measured according to manufacturers’ instructions at indicated time points. In
brief, an aliquot of the supernatant was taken and Lysis Solution was added for 45
min to induce maximal LDH release before another aliquot of the supernatant was
taken. Subsequently, the supernatants were incubated with CytoTox 96® Reagent
for 15 min protected from light at room temperature before adding Stop Solution.
Absorbance was measured at 490 nm.
siRNA treatment in HT1080 cells. HT1080 cells were plated in a petri dish in 15
ml antibiotic-free medium. After 24 h 180 pmol RNAi and 24 μl LipofectamineTM
(Thermo Fisher) were each mixed in 1.5 ml Opti-MEM® I Medium (Thermo
Fisher) without serum, combined and incubated at room temperature for 20 min
before dropping the mixture on the cells. The following day, cells were replated into
six-well-plates and treated with ferroptosis inducers and/or inhibitors after 24 h
and subsequently analyzed via FACS.
CellTiter-Glo® luminescent cell viability assay. Cells were plated in an opaque-
walled 96-well plate and treatment with ferroptosis inducers and/or ferroptosis
inhibitors was initiated 24 h later. After the established treatment schedule, the
CellTiter-Glo® Luminescent Cell Viability Assay (also see Supplementary Table 2 for
details) was used to quantify the amount of ATP in each well to detect the presence
of metabolically active cells. Here, the reaction agent was directly added to the wells,
mixed on an orbital shaker for 2 min, and then incubated at room temperature for
10min. The luminescence was detected using a Promega GloMax® instrument.
Time-lapse imaging. Time-lapse imaging was performed using a 2.5×/0.12 Fluar
objective for the primary murine tubular cells and a 5×/0.25 Fluar objective for the
primary murine renal tubules on an Axiovert 200M equipped with a large incu-
bation chamber (37 °C), 5% CO2, and humidity control. Transmitted light and
fluorescent images (LED 475 nm os Spectra X light source, emission filter BP 525/
50) were acquired using an Orca flash 4.0 camera. Primary murine renal tubules
were isolated without glycine in any of the solutions and transferred in a six-well
plate containing their respective medium as mentioned in the section “Isolation of
primary murine renal tubules”. Primary murine tubular cells that were passaged
once were treated with RSL3 diluted in their respective medium as mentioned in
the section “Generation, cell culture and induction of cell death in primary murine
tubular cells”. Additionally, 50 nM SYTOX Green nucleic acid stain (Life Tech-
nologies) was added to visualize the necrotic primary murine tubular cells. The live
imaging procedure was supported by the Light Microscopy Facility, a Core Facility
of the CMCB Technology Platform at TU Dresden.
Assessment of radical trapping antioxidant properties
Inhibited co-autoxidations of cumene. Cumene was washed three times with 1 M
NaOH, distilled H2O, and brine as previously established30. The organic fraction
was dried using MgSO4, filtered, and distilled under reduced pressure. The distillate
was then purified by percolation through silica, followed by basic alumina. To a
cuvette, 1.25 ml cumene (3.6 M) and 1.18 ml PhCl were added and equilibrated at
37 °C for 15 min in the thermostatted sample holder of a UV−Vis spectro-
photometer. STY-BODIPY (12.5 μl of a 2 mM stock solution in 1,2,4-tri-
chlorobenzene) and AIBN (50 μL of 0.3 M stock solution in PhCl) were added and
the solution was thoroughly mixed. After 45 min, the test compound (10 μL of 500
μM or 2.5 mM stock solution in PhCl) was added and the loss of absorbance was
monitored at 571 nm (εSTY-BODIPY= 128, 141M−1 cm−1). Experiments were per-
formed in triplicate using HPLC grade solvents and kinetic data is given as an
average of three independent measurements.
Inhibited co-autoxidation of egg phosphatidylcholine liposomes. Based on a pre-
viously published method27–29, to a black 96-well polypropylene plate, a solution of
egg phosphatidylcholine liposomes (1 mM), STY-BODIPY (1 μM), and
MeOAMVN (0.2 mM) in PBS at pH 7.4 were added to a final volume of 295 μl.
Inhibitors were then added (5 μl aliquots) at desired concentrations to the
appropriate wells followed by vigorous mixing. The plate was equilibrated to 37 °C
and data was collected using a BioTek Synergy H1 plate reader by excitation of the
probes at 488 nm and emission was measured at 518 nm. The raw data were
transformed by dividing the obtained RFU values by the response factor of 2.90 ×
104 RFU/μM (specific to gain 70 on the aforementioned instrument). Experiments
were performed in triplicate using HPLC grade solvents and kinetic data is given as
an average of three independent measurements. Experiments were performed in
triplicate using HPLC grade solvents and kinetic data is given as an average of three
independent measurements.
Assessment of metabolic stability in human liver microsomes. To determine
metabolic stability in human liver microsomes (pooled, mixed gender; XenoTech,
H0630/lot N# 1610016) Nec-1f was assessed using HPLC-MS. Metabolic stability
was defined as the percentage of parent compound lost over time in the presence of
a metabolically active test system. For this, microsomal incubations were carried
out in 96-well plates in five aliquots of 40 μl each (one for each time point). Liver
microsomal incubation medium comprised of phosphate buffer (100 mM, pH 7.4),
MgCl2 (3.3 mM), NADPН (3 mM), glucose-6-phosphate (5.3 mM; Sigma-Aldrich),
glucose-6-phosphate dehydrogenase (0.67 units/ml, from baker’s yeast, type XV;
Sigma-Aldrich) with 0.42 mg of liver microsomal protein per ml. In the control
reactions with diclofenac (Enamine) and propanolol (Sigma-Aldrich) the NADPH-
cofactor system was substituted with phosphate buffer. Dissolved Nec-1f (2 μM,
final solvent concentration 1.6 %) was incubated with microsomes at 37 °C, shaking
at 100 rpm. Each reaction was performed in duplicates. Five time points over 40
min were analyzed. The reactions were stopped by adding ten volumes of 90%
acetonitrile-water (Sigma-Aldrich) to incubation aliquots, followed by protein
sedimentation by centrifuging at 14.000×g for 3 min. Supernatants were analyzed
using the HPLC system coupled with tandem mass spectrometer (also see Sup-
plementary Table 3 for details). The elimination constant (kel), half-life (t1/2), and
intrinsic clearance (Clint) were determined in the plot of ln(AUC) versus time,
using linear regression analysis:


















where ClH is a hepatic clearance (ml/min/kg), ClH= EQH
QH = liver blood flow (mlmin/kg)2
E = extraction ratio, assumed at 0.3 for low clearance and at 0.7 for high clearance
compounds
fu = fraction unbound in plasma, assumed at 1.
The Clint classification values were calculated for mouse, rat, and human species
using the literature data on liver weight and microsomal protein concentration40,41
and are represented in the following table.
The intrinsic clearance groups for the classification of test compounds are
shown below.
Fig. 6 Nec-1f protects against bilateral renal ischemia-reperfusion injury in mice. C57Bl/6 N mice underwent bilateral ischemia as detailed in the
methods section. A Representative images of 4-Hydroxynonenal (4HNE)-staining, quantified in (B, n = 4). C Representative periodic acid-Schiff (PAS)-
stained histological sections are presented and quantified using the tubular damage score (D, n = 4). Serum concentrations of E creatinine (sham n = 2,
48 h IRI vehicle n = 12, Nec-1f n = 10, 72 h IRI vehicle n = 8, Nec-1f n = 6) and F urea (sham n = 2, 48 h IRI vehicle n = 12, Nec-1f n = 11, 72 h IRI vehicle n
= 6, Nec-1f n = 6) were measured in two independent experiments 48 and 72 h following the onset of reperfusion. G F4/80 positivity was stained by
immunohistochemistry and quantified by experienced nephropathologists (H, I, n = 5). Bar graphs represent the mean +/− SD. J Kaplan−Meier survival
curves following severe renal ischemia-reperfusion injury upon pre-treatment with 2 mg Fer-1/kg body weight, 2 mg Nec-1s/kg body weight, 2 mg Nec-1f/
kg body weight, or vehicle control are shown. Differences in the survival curves of vehicle compared to Fer-1 or Nec-1s are not statistically significant. All
experiments were performed in a strictly double-blinded manner. Statistical analysis was performed using a two-sided student’s t-test. *p < 0.05; n.s. not
significant.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24712-6
10 NATURE COMMUNICATIONS |         (2021) 12:4402 | https://doi.org/10.1038/s41467-021-24712-6 | www.nature.com/naturecommunications
Classification group Intrinsic clearance (µl/min/mg protein)
Mouse Rat Human
Low clearance < 8.6 < 13 < 8.8
High clearance > 48 > 72 > 48
Assessment of stability in human plasma. To determine the stability of the Nec-
1f in human plasma (plasma stability assay was carried by ENAMINE Ltd.,
Ukraine), Nec-1f and reference compounds were analyzed and compared at five
time points over 120 min using HPLC-MS/MS. Plasma stability is defined as the
percentage of parent compound remaining in plasma over the time. Here, incu-
bations were carried out in 5 aliquots of 70 µl each (one for each time point), in
duplicates. Nec-1f and respective controls (1 µM, final DMSO concentration 1%)
were incubated at 37 °C with shaking at 100 rpm. Five time points over 120 min
have been analyzed. The reactions were stopped by adding 420 µl of acetonitrile-
water mixture (90:10) with subsequent plasma proteins sedimentation by cen-
trifuging at 14.000 × g for 5 min. Supernatants were analyzed by the HPLC system
coupled with tandem mass spectrometer. The percentage of the test compounds
remaining after incubation in plasma and their half-lives (T1/2) was calculated.
In vitro off-target pharmacology study and IDO assay. Potential binding
partners of Nec-1f at a concentration of 10 μM were assessed by Eurofins Discovery
Services, Celle L´Evescault, France. Compound binding to recombinant proteins
was calculated as inhibition (in percent) of the binding of a radioactively labeled
ligand specific for each target according to the Eurofins standard protocol. To
determine the inhibitory activity of Nec-1f on indoleamine 2,3-dioxygenase (IDO),
the ability of IDO to mediate oxidative cleavage of L-tryptophan to N-formyl-
kynurenine was measured. Following pre-incubation of E. coli-derived human IDO
protein (20 nM) for 15 min at 25 °C with increasing concentrations of 0.1, 1, and
10 µM Nec-1f, 0.1 fM L-tryptophan (L-Trp) in the presence of 20 mM ascorbate,
3.5 μM methylene blue and 0.2 mg/ml catalase in 50 mM potassium phosphate
buffer (pH 6.5) was added and incubated for 2 h at 25 °C. The formation of N-
formyl-kynurenine was quantified by following the absorbance increase at 321 nm.
Mice. All mice used in this study were kept under stable 12-h circles of darkness
and light in the respective facilities. Room temperature was kept between 20 and
24 °C and air humidity between 45 and 65% as documented in daily controls. If not
otherwise indicated, all cages were IVCs which fulfilled at least Euonorm type II.
Mice had access to sterilized standard pellet food and water ad libidum. All cages
and nestlets were sterilized by autoclaving before use.
8- to 12-week-old mice were co-housed with 2−5 mice/cage in our facility at the
Medizinisch-Theoretisches Zentrum (MTZ) at the Medical Faculty of the
Technische Universität of Dresden (TU Dresden). Matching wild-type mice
(C57Bl/6N) were initially provided by Charles River, Sulzfeld, Germany, at the age
of 6−7 weeks. Gpx4cys/− mice were described previously42. In brief, the
selenocysteine of GPX4 was genetically changed to a cysteine, resulting in
compromised GPX4-activity. To drive the Gpx4 mutation-initiating Cre, mice
received an intraperitoneal dose of tamoxifen (2 mg in 100 µl SMOFlipid, HEXAL)
at days 1 and 3, whereas the experiments were performed from day 15 on. Mice not
harboring the Cre recombinase and mice not containing the Gpx4 mutation also
received tamoxifen at days 1 and 3 and were considered controls. Specific
information regarding the Fsp1-deficient mice (B6.129-Aifm2tm1Marc/Ieg) is
available at http://www.informatics.jax.org/strain/MGI:590505219. All experiments
were conducted in a strictly blinded manner regarding genotypes and small
molecules. All experiments were performed according to German animal
protection laws and were approved by German ethics committees and local
authorities in Kiel (ethics committee of the CAU Kiel and the Umwelt- und
Landwirtschaftsministerium Schleswig-Holstein, respectively) and Dresden (ethics
committee of the TU Dresden and the Landesdirektion Sachsen, respectively). Sex-
matched, 6–10-week-old C57BL/6 (The Jackson Laboratory, Bar Harbor, ME) and
C57BL/6 LysM-GFP mice (provided by M. Miller, Washington University in St.
Louis and originally obtained from K. Ley, La Jolla Institute for Allergy and
Immunology, La Jolla, CA) were utilized for intravital imaging of transplanted
hearts. Heart transplant experiments were approved by the Institutional Animal
Studies Committee at Washington University.
Isolation of primary murine renal tubules. Primary murine renal tubules were
isolated following a modified previously established protocol14. In detail (demon-
strated in Fig. S7), murine kidneys were removed, washed with PBS, decapsulized,
and sliced in four to five slices. Kidney slices of each kidney were transferred in 2
ml reaction tube containing 2 mg/ml collagenase type II in incubation solution (48
μg/ml trypsin inhibitor, 25 μg/ml DNAse I, 140 mM NaCl, 0.4 mM KH2PO4, 1.6
mM K2HPO4 · 3 H2O, 1 mM MgSO4 · 7 H2O, 10 mM CH3COONa · 3 H2O, 1 mM
α-ketoglytarate and 1.3 mM Ca-gluconate) and digested for 5 min at 37 °C, 850
rpm. Due to the presence of damaged tubules, the first resulting supernatant was
discarded and 1 ml of 2 mg/ml collagenase type II in incubation solution was added
to the kidney slices and digested for 5 min at 37 °C, 850 rpm. The supernatant was
collected and transferred in a 2 ml reaction tube containing 1 ml ice-cold sorting
solution (0.5 mg/ml bovine albumin in incubation solution). The reaction tubes
were left on ice for the tubules to precipitate. The supernatant was removed and the
tubules were washed twice with ice-cold incubation solution. Once the tubules
precipitated the supernatant was removed and the ice-cold sorting solution was
added (the volume was adjusted depending on the number of samples needed for
the experiment). Tubules were distributed in a twenty-four-well plate containing
Dulbecco’s Modified Eagle Medium F-12 Nutrient Mixture without phenol red
(DMEM/F12, Thermo Fisher), supplemented with 0.01 mg/ml recombinant human
insulin, 5.5 μg/ml human transferrin, 0.005 μg/ml sodium selenite (Na2SeO3) (ITS
without linoleic acid, Sigma Aldrich), 50 nM hydrocortisone, 100 U/ml penicillin,
and 100 μg/ml streptomycin (Pen/Strep, Thermo Fisher).
Generation, cell culture, and induction of cell death in primary murine tubular
cells. Murine tubular cells were generated by outgrowth from isolated renal tubules
(see above). Primary murine tubules were placed in six-well plates containing
Dulbecco’s Modified Eagle Medium F-12 Nutrient Mixture without phenol red
(DMEM/F12, Thermo Fisher), supplemented with 0.01 mg/ml recombinant human
insulin, 5.5 μg/ml human transferrin, 0.005 μg/ml Na2SeO3 (ITS without linoleic
acid, Sigma Aldrich), 50 nM hydrocortisone, 100 U/ml penicillin, and 100 μg/ml
streptomycin (Pen/Strep, Thermo Fisher). After two days, the outgrown primary
murine tubular cells were washed with PBS and a fresh medium was added. When
the number of primary murine tubular cells reached approximately 50%
confluence, the cells were removed from the six-well plates using Trypsin-EDTA
(Thermo Fisher), washed with medium and a Ficoll Paque Plus (Sigma Aldrich)
gradient was performed to remove any dead cells, and debris from the murine renal
tubules. Cells were washed twice with PBS and seeded in six-well plates with
medium. Once the number of grown cells reached approximately 50% confluence,
they were washed with PBS and treated with type 2 FIN: RSL3 (also see
Supplementary Table 2 for details). After 14 h, medium and cells were collected
and prepared for LDH release assay. Images of the treated primary murine tubular
cells were obtained using a 20×/0.30 PH1 objective on a Leica DMi1 microscope.
Induction of cell death in murine renal tubules. All of the experiments per-
formed contain a negative control to assess LDH release at 0 h of incubation as a
quality control. No more than 10% LDH release in these negative controls was
tolerated. In these tubules, necrotic cell death occurs spontaneously as demon-
strated, but can be accelerated by the addition of ferroptosis-inducing agents such
as RSL3. Isolated murine renal tubules were placed in twenty four-well plates
containing the respective agents diluted in Dulbecco’s Modified Eagle Medium F-
12 Nutrient Mixture without phenol red (DMEM/F12, Thermo Fisher), supple-
mented with 0.01 mg/ml recombinant human insulin, 5.5 μg/ml human transferrin,
0.005 μg/ml Na2SeO3 (ITS without linoleic acid, Sigma Aldrich), 50 nM hydro-
cortisone, 100 U/ml penicillin, and 100 μg/ml streptomycin (Pen/Strep, Thermo
Fisher). After the indicated time points, the medium of each well was collected and
tubules were prepared for an LDH release assay. Images of the treated murine renal
tubules were obtained using a 20x/0.30 PH1 objective on a Leica DMi1 microscope.
Cisplatin-induced acute kidney injury (CP-AKI). As reported earlier43, female
mice were rigorously matched for weight, age, and genetic background. Each
mouse received a single dose of cisplatin (20 mg/kg) intraperitoneally in a total
volume of 400 µl PBS. Following injection, mice were returned into cages (2−5
animals per cage) and monitored closely. After 48 h, retro-orbital blood collection
was performed and mice were sacrificed by cervical dislocation. The right kidney
was put in 4% normal buffered formalin for 24 h and then transferred to 70%
ethanol for storage at room temperature. Correspondingly, the left kidneys were
sorted into an Eppendorf tube and shock frozen in liquid nitrogen.
Bilateral kidney ischemia and reperfusion injury model (IRI)
Surgical protocol. All male mice were strictly matched for weight, age, and genetic
background. Bilateral kidney ischemia and reperfusion injury (IRI) was performed
as described in detail earlier43. In essence, 15 min prior to surgery, all mice received
0.1 µg/g body weight buprenorphine-HCl intraperitoneally for analgesia. Anes-
thesia was induced by the application of 3 l/min of volatile isoflurane with pure
oxygen in the induction chamber of a COMPAC5 (VetEquip, the Netherlands)
small animal anesthesia unit. After achieving a sufficient level of narcosis, typically
within 2 min, mice were placed in a supine position on a temperature-controlled
self-regulated heating system calibrated to 38 °C and fixed with stripes at all
extremities. Anesthesia was reduced to a maintenance dose of 1.5 l/min isoflurane.
Breathing characteristics and levels of analgesia were closely assessed visually. The
abdomen was opened layer-by-layer to create a 2 cm wide opening of the abdomen.
Blunt retractors (Fine Science Tools (FST), Germany) were placed for convenient
access. The caecum and gut were carefully mobilized and placed to the left side,
where they were placed on a PBS-soaked sterile gauze. The second piece of PBS-
soaked gauze was used to sandwich the gut, deliberately lifting the duodenum to
visualize the aorta abdominalis. A cotton bud was used to gently push the liver
cranially to fully access the right renal pedicle. With the use of a surgical micro-
scope (Carl Zeiss, Jena, Germany), sharp forceps were used to pinch retroperitoneal
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holes directly cranially and caudally in the renal pedicle. Via this access, a 100 g
pressure micro serrefine (FST 18055-03) was placed on the pedicle to induce
ischemia and a timer was started. The cotton bud was removed, and the packed gut
switched to the right side of the mouse to visualize the left renal pedicle. If required,
the cotton bud was used to gently push aside the spleen or stomach. Once again,
retroperitoneal access was achieved by pinching holes with sharp forceps and
another 100 g pressure micro serrefine was placed. The time between the placement
of both serrefines was recorded (typically 40 s, controlled in all cases to under 1:00
min), the gut was returned into the abdominal cavity and the opening was covered
with the two gauze pieces. Twenty-nine minutes after initially starting the timer,
the retractors were put in place again and the gut again mobilized and packed to
visualize the right kidney. After exactly 30 min (1 s tolerance), the vascular clamp
was removed and the gut switched to the right side. After the recorded time
difference, this clamp was removed as well. Reperfusion was determined visually
for both sides before the gut was returned into the abdominal cavity. The parietal
peritoneum and the cutis, respectively, were closed separately by continuous seams
using a 6-0 monocryl thread (Ethicon). Isoflurane application was stopped
immediately thereafter and 1 mL of pre-warmed PBS was administered intraper-
itoneally to compensate for any possible dehydration during surgery and to control
for potential leakiness of the seams. The mice were divided into pairs of two and
put back into the cages. 0.1 µg/g buprenorphine-HCl was administered every 8 h
for analgesia. After a 48-h observation period, blood was collected by retroorbital
puncture and the mice were sacrificed by neck dislocation. The right kidney was
removed to be fixed for 24 h in 4% normal buffered formalin and transferred to
70% ethanol for storage at room temperature. The left kidney was removed and
shock frozen in liquid nitrogen before transfer to −80 °C for storage.
Moderate and severe models of IRI. In this study, we applied two different doses of
ischemia, a severe and a moderate model. The time of ischemia before the onset of
reperfusion in the model of moderate IRI was 30 min (Fig. 1B–I, Fig. S2A–D, and
Fig. 6A–I) and in the model of severe IRI was 38 min (Figs. 1A and 6J), respec-
tively. Otherwise, the two models are identical.
Acute oxalate nephropathy. C57BL/6N mice were procured from Charles River
Laboratories (Sulzfeld, Germany) and co-housed in groups of four in filter top
cages with unlimited access to food and water. Cages, nestlets, food, and water were
sterilized by autoclaving before use. Mice received a single intraperitoneal (i.p.)
injection of 100 mg/kg sodium oxalate (Santa Cruz Biotechnology) and 3% sodium
oxalate in drinking water and kidneys were harvested after 24 h. As a therapeutic
strategy, mice received a single dose of 10 mg/kg Nec-1f or vehicle control (10%
DMSO and PBS) 30 min before sodium oxalate injection. Blood and kidneys were
collected at sacrifice by cervical dislocation. The middle section of each kidney was
fixed for 24 h in formalin to be embedded in paraffin for histological analysis.
Intrarenal crystal precipitations were quantified by Pizzolato staining44. The
experimental procedure was approved by the Regierung von Oberbayern,
München, Germany (ROB-55.2-2532.Vet_02-18-127).
Intravital imaging of transplanted hearts. Hearts harvested from wild-type
C57BL/6 mice were transplanted into the right neck of syngeneic LysM-GFP hosts, as
previously described36. Recipient mice received no treatment or were treated with
Nec-1f (2 mg/g body weight intraperitoneally at the start of the heart transplant
procedure). Intravital two-photon imaging was performed using a custom-built
microscope running ImageWarp version 2.1 acquisition software (A&B Software). For
time-lapse imaging of cell trafficking, we averaged 15 video-rate frames (0.5 s per
slice) during the acquisition. Each plane represents an image of 220 × 240 μm in the x
and y dimensions and twenty-one sequential planes were acquired in the z dimension
(2.5-μm each). Each individual neutrophil was tracked from its first appearance in the
imaging window and followed up to the time point at which it dislocated more than
20 μm from its starting position. Fifty microlitres PBS containing 15 μl 655-nm
nontargeted Q-dots (Thermo Fisher Scientific) were injected prior to imaging to
visualize coronary vessels and assess whether neutrophils were intravascular or
extravascular. The number of extravascular neutrophils was divided by the sum of
intravascular and extravascular neutrophils to calculate extravasation. Imaris (Bit-
plane) was used for multidimensional rendering and manual cell tracking.
Immunohistology and semi-quantitative scoring. Organs were dissected as
indicated in each experiment and put in 4% (vol/vol) neutral-buffered for-
maldehyde, fixated for 24 h, and then transferred to 70% ethanol for storage. For
histologies, the kidneys were dehydrated in a graded ethanol series and xylene, and
finally embedded in paraffin. Paraffin sections (3–5 μm) were stained with periodic
acid–Schiff (PAS) reagent, according to standard routine protocol. Stained sections
were analyzed using an Axio Imager microscope (Zeiss) at 100×, 200×, and 400×
magnification. Micrographs were digitalized using an AxioCam MRm Rev. 3
FireWire camera and AxioVision ver. 4.5 software (Zeiss). Organ damage was
quantified by two experienced pathologists in a double-blind manner on a scale
ranging from 0 (unaffected tissue) to 10 (most severe organ damage).
For the scoring system, tissues were stained with PAS, and the degree of
morphological involvement in renal failure was determined using light microscopy.
The following parameters were chosen as indicative of morphological damage to
the kidney after ischemia-reperfusion injury (IRI): brush border loss, red blood cell
extravasation, tubule dilatation, tubule degeneration, tubule necrosis, and tubular
cast formation. These parameters were evaluated on a scale of 0–10, which ranged
from not present (0), mild (1–4), moderate (5 or 6), severe (7 or 8), to very severe
(9 or 10). Each parameter was determined on at least five different animals.
For 4-HNE stainings (also see Supplementary Table 1 for details), the slides were
blocked using 3% H2O2 followed by antigen retrieval using target retrieval solution
(Dako Deutschland GmbH) and boiling in a pressure cooker for 2.5min. Afterward,
sections were blocked with avidin-biotin blocking kit (Vector laboratories) and for 30
min with 5% skim milk (Bio-Rad Laboratories GmbH) and 20% normal goat serum
(Vector Laboratories, Burlingame) in 50mM Tris, pH 7.4. After blocking sections were
incubated overnight with polyclonal rabbit anti-4-Hydroxynonenal antibody (Abcam)
diluted in 1% BSA in 50mM Tris, pH 7.4 at 4 °C. Primary antibody was detected using
biotinylated goat anti-rabbit secondary antibody, ABC-kit, and ImmPACT-DAB as
substrate (all from Vector Laboratories). After counterstaining with hemalaun (Merck
KGaA, Darmstadt, Germany) sections were examined using a light microscope (Zeiss
Axio Imager.A2, Zeiss GmbH). For negative controls, the primary antibody was
omitted and replaced with a blocking solution. At least 12 fields of vision (at 200×
magnification) per cross-section from each kidney were evaluated and the degree of 4-
HNE-positive tubuli was analyzed using a semi-quantitative score ranging from 0-3: 0
= no staining; 1 = weak granular staining in 1–2 tubules per field of vision; 2 = clear
granular and weak diffuse tubular staining in more than 2 tubuli per field of vision; 3
= strong granular and diffuse staining. Mean scores from all analyzed field of visions
were calculated.
The tubular injury was scored by detecting the percentage of necrotic structures,
dilated tubules, casts and cellular infiltrates per HPF. To do so a grid with a raster
size of 2.5% of the total image area was imposed on top of each image and the
number of squares covering either of the histopathological features was counted
individually or as a composite (summary score). Pizzolato’s staining visualized
calcium oxalate crystals and crystal deposit formation in the kidney was evaluated
the following: no deposits = 0 point; crystals in papillary tip = 1 point; crystals in
cortical medullary junction = 2 points; crystals in cortex = 3 points. When crystals
were observed in multiple areas, the points were combined.
A TUNEL kit (Cell death detection kit, Roche) was used to quantify the number
of cells with DNA strand breaks per HPF. The green fluorescent area was measured
and the number of stained cells per slide was counted.
Pharmacokinetic analysis of Nec-1f in mice (tissue PK studies). This study was
initiated to determine the pharmacokinetic characteristics of the Nec-1f in mice
following i.p. administration. Experiments were conducted by Enamine, Ltd,
Ukraine. Levels of the Nec-1f were determined by LC-MS/MS in the blood plasma,
whole blood, brain, liver, kidney, heart, lung, and pancreas over time after a single
dose. 8−9 weeks old male C57BL/6 mice were used in this study. Mice were
randomly assigned to treatment groups before the pharmacokinetic study. Mice
were fasted for 3–4 h before dosing. Nine time points (5, 15, 30, 60, 120, 240, 360,
480, and 1.440 min) were set for the pharmacokinetic study. Groups of three mice
were used for each time point. Nec-1f was administered at 2 mg/ml.
Mice were i.v. injected with 2,2,2-tribromoethanol (Sigma-Aldrich) at the dose of
150mg/kg prior to blood collection from the orbital sinus in microtainers containing
K2EDTA (150 μl of whole blood was taken into a 1.5ml tube, the residue was
centrifuged at 5.500 × g) and sacrificed by cervical dislocation. Tissues samples (brain
(left lobe), left kidney, liver (large lobe fragment), lungs (both), pancreas, heart) were
processed immediately, snap-frozen, and stored at −70 °C for subsequent analysis.
Plasma (40 μl) and tissue samples (weight 100 ± 1mg) were homogenized with
400 μl of the internal standard solution IS400 using steel or zirconium oxide beads
(115 ± 5 mg) in The Bullet Blender® homogenizer for 30–120 s and centrifuged for
4 min at 14.000 × g. Two microliters of each sample were injected into LC-MS/MS
system. Diclofenac (400 ng/ml in water−methanol mixture 1:9, v/v) was used as a
standard for quantification of Nec-1f in plasma, blood, liver, heart, lung, pancreas,
and kidney as well as in brain (400 ng/ml in water-methanol mixture 1:9, v/v)
samples. Concentrations of Nec-1f were then determined using HPLC-MS/MS
using the following conditions: column: Phenomenex Luna C18(2) (50 × 2 mm, 5
μm), mobile phase А: acetonitrile (Sigma-Aldrich): water: formic acid (Sigma-
Aldrich) = 50: 950: 1, mobile phase B: acetonitrile: formic acid = 100: 0.1, linear
gradient: 0 min 0% B, 0.9 min 100% B, 1.1 min 100% B, 1.11 min 5% B, 2.8 min
stop, elution rate: 400 μL/min. A divert valve directed the flow to the detector from
1.65 to 2.25 min, column temperature: 30 °C, scan type: positive MRM, ion source:
turbo spray, ionization mode: ESI, nebulize gas: 15 l/min, curtain gas: 8 L/min,
collision gas: 4 l/min, ionspray voltage: −4.200 V, temperature: 400 °C.
Calibration standards for analysis of Nec-1f in plasma, blood, and tissue
samples were established as follows: The stock solution was consecutively diluted
with IS400 to get a series of calibration solutions with final concentrations of
10.000, 5.000, 2.500, 1.000, 500, 200, 100, 50, 20, 10, 5, and 2 ng/ml. Where
necessary, samples were homogenized with 400 µl of corresponding calibration
solution using zirconium oxide beads (115 ± 5mg) in The Bullet Blender®
homogenizer for 30 s at speed 8. Calibration curves were constructed using blank
samples of the respective tissue.
To obtain calibration standards, blank samples were mixed with 200−400 μl of
corresponding calibration solution. After mixing by pipetting and centrifugation for 4
min at 15.000 × g, 2 μl of each supernatant was injected into LC-MS/MS system.
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The pharmacokinetic data analysis was performed using noncompartmental,
bolus injection, or extravascular input analysis models in WinNonlin 5.2
(PharSight). Data below the lower limit of quantitation (LLOQ) were presented as
missing to improve the validity of t1/2 calculations. Measurements were performed
using Shimadzu Prominence HPLC (also see Supplementary Table 3 for details)
system including vacuum degasser, gradient pumps, reverse phase HPLC column,
column oven, and autosampler. Mass spectrometric analysis was performed using
an API 4.000 QTRAP mass spectrometer from Applied Biosystems/ MDS Sciex
(AB Sciex) with Turbo V ion source and TurboIonspray interface. The
TurboIonSpray ion source was used in both positive and negative ion modes. The
data acquisition and system control were performed using Analyst 1.6.3 software
from AB Sciex (Canada).
Statistical analysis. Statistical analyses were performed using Prism 8 (GraphPad
software, San Diego, CA, USA). To test the null hypothesis of no difference
between groups in the survival experiments we plotted the animals in a Kaplan-
Meier curve and used the log-rank test for statistics. Mouse data on damage scores
and serum levels of creatinine and urea were analyzed by a two-tailed parametric t-
test. In all other experiments, a two-sided t-test was used for normally distributed
data sets, and one-way ANOVA followed by post hoc Tukey’s multiple compar-
isons test was used for analyzing data from FACS analysis to compare multiple
treatments. Data were considered significant when * p < 0.05, ** p < 0.01, *** p <
0.001, **** p < 0.0001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data has been made available for this paper. Any additional data generated
supporting the findings of this study will be made available from the corresponding
author upon reasonable request. Source data are provided with this paper.
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